JAK inhibitors in dermatology: The promise of a new drug class - 18/04/17
Abstract |
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases. Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition might be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.
Le texte complet de cet article est disponible en PDF.Key words : alopecia areata, atopic dermatitis, baricitinib, JAK inhibitor, JAK-STAT, psoriasis, ruxolitinib, tofacitinib, vitiligo
Abbreviations used : AA, AD, AT, AU, CANDLE, FDA, IFN, IL, JAK, TH2, SALT, SAVI, STAT, Tyk2
Plan
Funding sources: Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. |
|
Conflicts of interest: Dr King has served on advisory boards or is a consultant for Aclaris Therapeutics Inc, Pfizer Inc, Eli Lilly and Company, and Concert Pharmaceuticals Inc. Dr Damsky has no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 76 - N° 4
P. 736-744 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?